News

ZAS Group is strengthening its internal core as it prepares for its “Next Wave” of progress. The company’s Managing Director is actively engaging with the ZAS Hematology team, fostering meaningful conversations designed to align every member with the organization’s forward-looking vision. These direct interactions underscore ZAS’s commitment to collaborative growth, reinforcing team bonds and fueling

ZAS Group is strengthening its internal core as it prepares for its “Next Wave” of progress. The company’s Managing Director is actively engaging with the ZAS Onco 1 team, fostering meaningful conversations designed to align every member with the organization’s forward-looking vision. These direct interactions underscore ZAS’s commitment to collaborative growth, reinforcing team bonds and

ZAS Group is strengthening its internal core as it prepares for its “Next Wave” of progress. The company’s Managing Director is actively engaging with the ZAS Bioplasma team, fostering meaningful conversations designed to align every member with the organization’s forward-looking vision. These direct interactions underscore ZAS’s commitment to collaborative growth, reinforcing team bonds and fueling

ZAS Group is strengthening its internal core as it prepares for its “Next Wave” of progress. The company’s Managing Director is actively engaging with the Leaders Team fostering meaningful conversations designed to align every member with the organization’s forward-looking vision. These direct interactions underscore ZAS’s commitment to collaborative growth, reinforcing team bonds and fueling a

Hamburg & Dassow, Germany | 14–17 May 2025ZAS Corporation proudly participated in the 20th anniversary celebration of Aqvida GmbH, one of Europe’s most respected oncology pharmaceutical companies. The global event, held in Hamburg and Dassow, brought together healthcare leaders and partners from over 35 countries to commemorate two decades of innovation and excellence in cancer

Rising Potential of a Pharmaceutical Exporter in Bangladesh The pharmaceutical industry in Bangladesh is experiencing remarkable growth, emerging not only as a self-sufficient market but as a serious contender in the global pharmaceutical trade. With its adaptability to stringent international regulatory standards, export diversification, and commitment to ethical practices, Bangladesh continues to cement its position

In a groundbreaking advancement for women’s healthcare in Bangladesh, ZAS Corporation, in collaboration with Canyon, has successfully launched Microwave Ablation for Fibroids for the very first time in the country. This innovative, minimally invasive procedure represents a new standard in fibroid treatment — offering faster recovery, reduced complications, and improved patient outcomes. The official launch

ZAS Ophthalmic, a concern of ZAS Group, proudly launched two innovative ophthalmic products — Timo-COMOD and Pollival — in the presence of distinguished ophthalmologists. This special event marked a significant milestone for ZAS Ophthalmic as it continues its commitment to bringing advanced, patient-friendly eye care solutions to Bangladesh. The launching program was held with the

ZAS recently hosted a masterclass on “Pharmaceutical Industry Future Trends by 2030,” where our team explored groundbreaking developments set to redefine the industry. The session offered eye-opening insights into emerging trends, empowering us to stay ahead of the curve and embrace innovation. With a clear understanding of the evolving landscape, ZAS is poised to lead